PT  - JOURNAL ARTICLE
AU  - Giulia Lamacchia
AU  - Alessio Mazzoni
AU  - Michele Spinicci
AU  - Anna Vanni
AU  - Lorenzo Salvati
AU  - Benedetta Peruzzi
AU  - Sara Bencini
AU  - Manuela Capone
AU  - Alberto Carnasciali
AU  - Parham Farahvachi
AU  - Arianna Rocca
AU  - Seble Tekle Kiros
AU  - Lucia Graziani
AU  - Lorenzo Zammarchi
AU  - Jessica Mencarini
AU  - Maria Grazia Colao
AU  - Roberto Caporale
AU  - Francesco Liotta
AU  - Lorenzo Cosmi
AU  - Gian Maria Rossolini
AU  - Alessandro Bartoloni
AU  - Laura Maggi
AU  - Francesco Annunziato
TI  - Clinical and immunological features of SARS-CoV-2 breakthrough infections in vaccinated individuals requiring hospitalization
AID  - 10.1101/2022.02.14.22270857
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.14.22270857
4099  - http://medrxiv.org/content/early/2022/02/15/2022.02.14.22270857.short
4100  - http://medrxiv.org/content/early/2022/02/15/2022.02.14.22270857.full
AB  - Background Waning immunity and the surge of SARS-CoV-2 variants are responsible for breakthrough infections, i.e. infections in fully vaccinated individuals. Although the majority of vaccinated infected subjects reports mild or no symptoms, some others require hospitalization. The clinical and immunological features of vaccinated hospitalized COVID-19 patients are currently unknown.Methods 29 unvaccinated and 36 vaccinated hospitalized COVID-19 patients were prospectively enrolled and clinical and laboratory data. Immunophenotyping of leukocytes’ subsets, T and B cell SARS-CoV-2 specific responses were evaluated via flow cytometry. Anti-IFN-α autoantibodies were measured via ELISA.Results Despite vaccinated patients were older and with more comorbidities, unvaccinated subjects showed higher levels of pro-inflammatory markers, more severe disease and increased mortality rate. Accordingly, they presented significant alterations in the circulating leukocyte composition, typical of severe COVID-19. Vaccinated patients displayed higher levels of anti-Spike IgGs and Spike-specific B cells. Of all participants, survivors showed higher levels of anti-Spike IgGs and S-specific CD4+ T cells than non-survivors. At hospital admission, 6 out of 65 patients (9.2%) displayed high serum concentrations of autoantibodies targeting IFN-α. Remarkably, 3 were unvaccinated and eventually died, while the other 3 were vaccinated and survived.Conclusion Despite more severe pre-existing clinical conditions, vaccinated patients have good outcome. A rapid activation of anti-SARS-CoV-2-specific immunity is fundamental for the resolution of the infection. Therefore, prior immunization through vaccination provides a significant contribute to prevention of disease worsening and can even overcome the presence of high-risk factors (i.e. older age, comorbidities, anti-IFN-α autoantibodies positivity).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by funds to the Department of Experimental and Clinical Medicine, University of Florence (Project Excellence Departments 2018-2022), by the University of Florence, project RICTD2122, by the Italian Ministry of Health (COVID-2020-12371849) and by Tuscany Region (TagSARS CoV 2).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics commitee of Azienda Ospedaliero Universitaria Careggi gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript